Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilene C Weitz

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Hematology (Amsterdam, Netherlands)|August 29, 2020
Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumabIoannis Tomazos, J Rafael Sierra, Karissa M Johnston, et al.
Obstetrics and Gynecology|February 7, 2020
Multidrug Therapy for Refractory Immune Thrombocytopenia in PregnancyAndrew H Chon, Randall Chan, Richard H Lee, et al.
Thrombosis and Haemostasis|August 28, 2002
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activationIlene C Weitz, Valerie K Israel, James R Waisman, et al.
Thrombosis Research|May 1, 2012
Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formationIlene C Weitz, Pedram Razavi, Leanne Rochanda, et al.
JACC. Case Reports|July 28, 2021
Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic SyndromeEdward Chau, Shiqian Li, Peter Z Xu, et al.
Annals of Hematology|March 23, 2024
Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL studyAlexander Röth, Wilma Barcellini, Tor Henrik Anderson Tvedt, et al.
Annals of Hematology|August 23, 2022
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL studyAlexander Röth, Wilma Barcellini, Tor Henrik Anderson Tvedt, et al.
Blood Advances|July 17, 2023
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-upAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
European Journal of Haematology|November 20, 2022
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA studyAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
Eclinicalmedicine|August 8, 2024
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extensionAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Hematology (Amsterdam, Netherlands)|August 29, 2020
Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumabIoannis Tomazos, J Rafael Sierra, Karissa M Johnston, et al.
Obstetrics and Gynecology|February 7, 2020
Multidrug Therapy for Refractory Immune Thrombocytopenia in PregnancyAndrew H Chon, Randall Chan, Richard H Lee, et al.
Thrombosis and Haemostasis|August 28, 2002
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activationIlene C Weitz, Valerie K Israel, James R Waisman, et al.
Thrombosis Research|May 1, 2012
Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formationIlene C Weitz, Pedram Razavi, Leanne Rochanda, et al.
JACC. Case Reports|July 28, 2021
Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic SyndromeEdward Chau, Shiqian Li, Peter Z Xu, et al.
Annals of Hematology|March 23, 2024
Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL studyAlexander Röth, Wilma Barcellini, Tor Henrik Anderson Tvedt, et al.
Annals of Hematology|August 23, 2022
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL studyAlexander Röth, Wilma Barcellini, Tor Henrik Anderson Tvedt, et al.
Blood Advances|July 17, 2023
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-upAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
European Journal of Haematology|November 20, 2022
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA studyAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
Eclinicalmedicine|August 8, 2024
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extensionAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
Pageof 4